Quick answers
- Is CVE-2026-79317 exploited in the wild?
- No. Junglewise Threat Intelligence has no report of CVE-2026-79317 being exploited in the wild.
- How severe is CVE-2026-79317?
- Medium severity, with a CVSS score of 4.8, published 21 September 2026.
- Which products and versions are affected?
- Vaxilu X-Ui 0.3.2.
- Is there a fix for CVE-2026-79317?
- No fixed version is recorded yet. Check the vendor's advisory in the references below. If you run it, Junglewise drafts a mitigation that fits your setup and applies it once you approve, with senior security engineers behind it.
- How is CVE-2026-79317 attacked?
- It is attacked over the network, in a web application.
- Am I affected by CVE-2026-79317?
- Check whether you run Vaxilu X-Ui at an affected version. Junglewise does that check for you around the clock: connect your code, cloud and domains, and it matches new vulnerabilities like this one against what you actually run and tells you when one reaches you.
Technical details
The vulnerability is an insufficient session expiration issue (CWE-613) where session state is entirely client-side in a signed cookie without server-side validation. When administrator credentials are changed, the server does not invalidate previously issued session cookies, and authorization checks do not re-validate the current password or session state against the database. An attacker holding a pre-change admin session cookie can bypass re-authentication and continue accessing the management interface.
Affected products
- vaxilu x-ui 0.3.2
Timeline
- 2026-08-04: disclosed
- 2026-09-21: advisory